Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation

Objective: This study evaluated the current incidence of pulmonary arteriovenous malformations (PAVMs) following stage 2 palliation (S2P). Methods: Patients who underwent S2P, either through a bidirectional cavopulmonary shunt (BCPS) or the Kawashima procedure (KP) between 1992 and 2022, were review...

Full description

Saved in:
Bibliographic Details
Main Authors: Lea Behrend, Thibault Schaeffer, Muneaki Matsubara, Jonas Palm, Teresa Lemmen, Nicole Piber, Paul Philipp Heinisch, Stanimir Georgiev, Alfred Hager, Peter Ewert, Jürgen Hörer, Masamichi Ono
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:International Journal of Cardiology Congenital Heart Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666668525000473
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849229230001356800
author Lea Behrend
Thibault Schaeffer
Muneaki Matsubara
Jonas Palm
Teresa Lemmen
Nicole Piber
Paul Philipp Heinisch
Stanimir Georgiev
Alfred Hager
Peter Ewert
Jürgen Hörer
Masamichi Ono
author_facet Lea Behrend
Thibault Schaeffer
Muneaki Matsubara
Jonas Palm
Teresa Lemmen
Nicole Piber
Paul Philipp Heinisch
Stanimir Georgiev
Alfred Hager
Peter Ewert
Jürgen Hörer
Masamichi Ono
author_sort Lea Behrend
collection DOAJ
description Objective: This study evaluated the current incidence of pulmonary arteriovenous malformations (PAVMs) following stage 2 palliation (S2P). Methods: Patients who underwent S2P, either through a bidirectional cavopulmonary shunt (BCPS) or the Kawashima procedure (KP) between 1992 and 2022, were reviewed. The cumulative incidence of PAVMs was compared between BCPS and KP. Risk factors for the development of PAVMs were identified. Results: Among 682 patients who underwent S2P, 661 (96.9 %) underwent BCPS and 21 (3.1 %) KP. Median age at S2P was 5.1 (interquartile ranges (IQR): 3.6–9.6) months. During the median interstage follow-up of 1.6 (IQR: 1.6–2.2) years, PAVMs developed in 11 (1.6 %) patients (1.1 % (n = 7) after BCPS and 19.0 % (n = 4) after KP). Cumulative incidence of PAVMs was higher in patients after KP than those after BCPS (p < 0.001). PAVMs were observed in the right lung in 9 patients and both lungs in two. One patient with biliary atresia died of progressive PAVMs and liver cirrhosis after KP, and the remaining 10 patients underwent Fontan completion with a median interval of 1.9 (IQR: 1.5–2.4) years. PAVMs improved in all patients (9 resolutions and 1 improved). Independent risk factors for the development of PAVMs were KP (hazard ratio (HR): 16.364, p < 0.001) in all patients, anomalous pulmonary venous connection (HR: 6.772, p = 0.023) in BCPS patients, and hypoplastic left heart syndrome (HR: 18.819, p = 0.018) in KP patients. Conclusions: The incidence of PAVMs after S2P is very low after BCPS but still relevant after KP. Resolution or improvement of PAVMs is probable after Fontan completion.
format Article
id doaj-art-4a073991249e4312b59fc76161b5cd4d
institution Kabale University
issn 2666-6685
language English
publishDate 2025-09-01
publisher Elsevier
record_format Article
series International Journal of Cardiology Congenital Heart Disease
spelling doaj-art-4a073991249e4312b59fc76161b5cd4d2025-08-22T04:58:28ZengElsevierInternational Journal of Cardiology Congenital Heart Disease2666-66852025-09-012110061110.1016/j.ijcchd.2025.100611Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliationLea Behrend0Thibault Schaeffer1Muneaki Matsubara2Jonas Palm3Teresa Lemmen4Nicole Piber5Paul Philipp Heinisch6Stanimir Georgiev7Alfred Hager8Peter Ewert9Jürgen Hörer10Masamichi Ono11Department of Congenital and Pediatric Heart Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig-Maximilians-Universität, Europäisches Kinderherzzentrum München, Munich, GermanyDepartment of Congenital and Pediatric Heart Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig-Maximilians-Universität, Europäisches Kinderherzzentrum München, Munich, GermanyDepartment of Congenital and Pediatric Heart Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig-Maximilians-Universität, Europäisches Kinderherzzentrum München, Munich, GermanyDepartment of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, University Hospital of Technische Universität München, Munich, GermanyDepartment of Congenital and Pediatric Heart Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig-Maximilians-Universität, Europäisches Kinderherzzentrum München, Munich, GermanyDepartment of Cardiovascular Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Munich, GermanyDepartment of Congenital and Pediatric Heart Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig-Maximilians-Universität, Europäisches Kinderherzzentrum München, Munich, GermanyDepartment of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, University Hospital of Technische Universität München, Munich, GermanyDepartment of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, University Hospital of Technische Universität München, Munich, GermanyDepartment of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, University Hospital of Technische Universität München, Munich, GermanyDepartment of Congenital and Pediatric Heart Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig-Maximilians-Universität, Europäisches Kinderherzzentrum München, Munich, GermanyDepartment of Congenital and Pediatric Heart Surgery, German Heart Center Munich, University Hospital of Technische Universität München, Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig-Maximilians-Universität, Europäisches Kinderherzzentrum München, Munich, Germany; Corresponding author. Department of Congenital and Pediatric Heart Surgery, German Heart Center Munich, Lazarettstraße 36, 80636, Munich, Germany.Objective: This study evaluated the current incidence of pulmonary arteriovenous malformations (PAVMs) following stage 2 palliation (S2P). Methods: Patients who underwent S2P, either through a bidirectional cavopulmonary shunt (BCPS) or the Kawashima procedure (KP) between 1992 and 2022, were reviewed. The cumulative incidence of PAVMs was compared between BCPS and KP. Risk factors for the development of PAVMs were identified. Results: Among 682 patients who underwent S2P, 661 (96.9 %) underwent BCPS and 21 (3.1 %) KP. Median age at S2P was 5.1 (interquartile ranges (IQR): 3.6–9.6) months. During the median interstage follow-up of 1.6 (IQR: 1.6–2.2) years, PAVMs developed in 11 (1.6 %) patients (1.1 % (n = 7) after BCPS and 19.0 % (n = 4) after KP). Cumulative incidence of PAVMs was higher in patients after KP than those after BCPS (p < 0.001). PAVMs were observed in the right lung in 9 patients and both lungs in two. One patient with biliary atresia died of progressive PAVMs and liver cirrhosis after KP, and the remaining 10 patients underwent Fontan completion with a median interval of 1.9 (IQR: 1.5–2.4) years. PAVMs improved in all patients (9 resolutions and 1 improved). Independent risk factors for the development of PAVMs were KP (hazard ratio (HR): 16.364, p < 0.001) in all patients, anomalous pulmonary venous connection (HR: 6.772, p = 0.023) in BCPS patients, and hypoplastic left heart syndrome (HR: 18.819, p = 0.018) in KP patients. Conclusions: The incidence of PAVMs after S2P is very low after BCPS but still relevant after KP. Resolution or improvement of PAVMs is probable after Fontan completion.http://www.sciencedirect.com/science/article/pii/S2666668525000473Pulmonary arteriovenous malformationsBidirectional cavopulmonary shuntKawashima procedureTotal cavopulmonary connection
spellingShingle Lea Behrend
Thibault Schaeffer
Muneaki Matsubara
Jonas Palm
Teresa Lemmen
Nicole Piber
Paul Philipp Heinisch
Stanimir Georgiev
Alfred Hager
Peter Ewert
Jürgen Hörer
Masamichi Ono
Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation
International Journal of Cardiology Congenital Heart Disease
Pulmonary arteriovenous malformations
Bidirectional cavopulmonary shunt
Kawashima procedure
Total cavopulmonary connection
title Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation
title_full Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation
title_fullStr Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation
title_full_unstemmed Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation
title_short Incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation
title_sort incidence and risk factors for the development of pulmonary arteriovenous malformations after stage 2 palliation
topic Pulmonary arteriovenous malformations
Bidirectional cavopulmonary shunt
Kawashima procedure
Total cavopulmonary connection
url http://www.sciencedirect.com/science/article/pii/S2666668525000473
work_keys_str_mv AT leabehrend incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT thibaultschaeffer incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT muneakimatsubara incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT jonaspalm incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT teresalemmen incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT nicolepiber incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT paulphilippheinisch incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT stanimirgeorgiev incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT alfredhager incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT peterewert incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT jurgenhorer incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation
AT masamichiono incidenceandriskfactorsforthedevelopmentofpulmonaryarteriovenousmalformationsafterstage2palliation